Valuation: Catalyst Pharmaceuticals, Inc.

Market Cap 3.85B 3.33B 3.13B 2.85B 5.35B 369B 5.44B 36.66B 14.33B 185B 14.47B 14.16B 613B P/E 2024
15.9x
P/E 2025 13.9x
Enterprise Value 3.15B 2.72B 2.56B 2.32B 4.37B 301B 4.44B 29.94B 11.71B 151B 11.82B 11.56B 501B EV / Sales 2024
4.02x
EV / Sales 2025 3.67x
Free-Float
99.94%
Yield 2024 *
-
Yield 2025 -
1 day+2.63%
3 months+4.20%
6 months+39.50%
Current year+35.01%
Current year 18.96
Extreme 18.965
27.4
1 year 16.15
Extreme 16.15
27.4
3 years 10.93
Extreme 10.93
27.4
5 years 4.12
Extreme 4.12
27.4
10 years 0.66
Extreme 0.657
27.4
Manager TitleAgeSince
Chief Executive Officer 65 01/01/2024
Director of Finance/CFO 55 01/01/2024
Chief Tech/Sci/R&D Officer 62 01/06/2025
Director TitleAgeSince
Director/Board Member 48 15/07/2026
Director/Board Member - 15/07/2026
Director/Board Member - 15/07/2026
Change 5-day change 1-year change 3-year change Capi.($)
+2.63%-.--% - - 3.85B
-0.31%+2.44%+41.97%-0.61% 80.23B
-1.02%-0.51%-2.54%+26.80% 50.69B
-3.10%-4.84%+9.26%+158.46% 46.87B
-0.74%+3.26%-49.46%-48.10% 46.34B
-0.39%+0.91%+55.50%-23.07% 31B
-0.52%+7.01%+137.24%-36.68% 25.28B
-0.30%-0.33%+39.46%+84.18% 24.36B
-1.42%-1.11%-2.29%+189.51% 20.81B
-1.83%-2.82%+61.91%+105.60% 16.08B
Average -0.70%+1.44%+32.34%+50.68% 37.96B
Weighted average by Cap. -0.98%+1.13%+24.82%+36.75%

Financials

2024 2025
Net sales 492M 425M 399M 363M 682M 47.02B 694M 4.68B 1.83B 23.55B 1.85B 1.81B 78.25B 589M 509M 478M 435M 817M 56.32B 831M 5.6B 2.19B 28.2B 2.21B 2.16B 93.72B
Net income 164M 142M 133M 121M 227M 15.67B 231M 1.56B 609M 7.85B 615M 602M 26.08B 214M 185M 174M 158M 297M 20.49B 302M 2.04B 797M 10.26B 805M 787M 34.11B
Net Debt -514M -444M -417M -380M -714M -49.18B -726M -4.89B -1.91B -24.63B -1.93B -1.89B -81.85B -706M -610M -573M -521M -980M -67.55B -996M -6.72B -2.63B -33.82B -2.65B -2.59B -112B
Logo Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
Employees
182
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB